1-ethyl-2-cyclopenten-1-ol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-ethyl-2-cyclopenten-1-ol
• 英文别名: 3-Ethyl-4-penten-3-ol；1-Ethylcyclopent-2-en-1-ol
• 化学式: C₇H₁₂O
• 分子量: 112.172
• InChiKey: BIECEEUAQKOZEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (Z)-7-Butyltellanyl-hept-6-en-3-one 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 以56%的产率得到1-ethyl-2-cyclopenten-1-ol
  参考文献：
  名称：

  羰基化合物存在下乙烯基碲化物与丁基锂反应的选择性

  摘要：

  研究了在-78°C下在羰基化合物（例如苯甲醛或环己酮）存在下用丁基锂在THF中处理异构化的乙烯基碲化物5-7的现象。观察到对碲原子的进攻的高选择性。在大多数情况下，获得了相应的烯丙醇作为唯一（或主要）产物，而不是通过在羰基化合物上1，2添加BuLi衍生的醇。使用酮烯丙二醛14代替乙烯基单碲化物获得了相似的结果。

  DOI：

  10.1016/s0040-4039(99)01567-1

文献信息

• 1,4-Addition of Diorganozincs to<b><i>α</i></b>,<b><i>β</i></b>-Unsaturated Ketones Catalyzed by a Copper(I)-Sulfonamide Combined System
  作者：Masato Kitamura、Takashi Miki、Keiji Nakano、Ryoji Noyori

  DOI：10.1246/bcsj.73.999

  日期：2000.4

  A mixture of CuCN and N-benzylbenzenesulfonamide catalyzes the 1,4-addition of dialkylzincs or diarylzincs (Cu : Zn = 1 : 200 to 1 : 10000) to α,β-unsaturated ketones to give, after aqueous workup, the corresponding β-substituted ketones in nearly quantitative yields. A range of cyclic enones having s-cis or s-trans geometries as well as conformationally flexible acyclic enones are usable as substrates

  CuCN 和 N-苄基苯磺酰胺的混合物催化二烷基锌或二芳基锌（Cu : Zn = 1 : 200 至 1 : 10000）与 α,β-不饱和酮的 1,4-加成反应，在水处理后得到相应的 β-以接近定量的产率取代酮。一系列具有 s-cis 或 s-trans 几何结构的环状烯酮以及构象灵活的无环烯酮可用作底物。乙基比甲基和苯基更容易迁移。CuOTf、CuO-t-C4H9 和甲基铜可用于代替 CuCN。在水处理之前，原位形成的烷基烯醇锌进一步与醛发生醇醛反应或 Pd(0) 辅助与乙酸烯丙酯偶联，产生区域控制的邻位碳缩合产物。
• Chiral phosphine–phosphite ligands in the enantioselective 1,4-addition of Grignard reagents to α,β-unsaturated carbonyl compounds
  作者：Qaseem Naeemi、Tobias Robert、Darius P. Kranz、Janna Velder、Hans-Günther Schmalz

  DOI：10.1016/j.tetasy.2011.04.018

  日期：2011.4

  phosphine–phosphite ligands was evaluated in the Cu-catalyzed asymmetric 1,4-addition of Grignard reagents to cyclopentenone, cycloheptenone and 5,6-dihydro-2H-pyran-2-one. TADDOL-based ligands 1a and 1b with a bulky substituent at the ortho-position to the chiral phosphite moiety gave rise to the 1,4-addition products with high enantioselectivities (up to 93% ee). In addition to ethyl-MgBr (as a standard

  在铜催化的格氏试剂对环戊烯酮，环庚烯酮和5,6-二氢-2 H-吡喃-2-酮的不对称1,4-加成反应中，评估了手性膦-亚磷酸酯配体库。在手性亚磷酸酯部分的邻位具有大取代基的基于TADDOL的配体1a和1b产生具有高对映选择性（至多93％ee）的1，4-加成产物。除了乙基-MgBr（作为标准的烷基亲核试剂）之外，还可以使用苯基-和异丙烯基-MgBr。就环戊烯酮而言，使用氯三甲基硅烷作为添加剂可提高区域选择性和对映选择性。
• Copper-catalyzed asymmetric conjugate addition with Grignard reagents and SimplePhos ligands
  作者：Laëtitia Palais、Alexandre Alexakis

  DOI：10.1016/j.tetasy.2009.11.016

  日期：2009.12

  Herein we report the copper-catalyzed asymmetric conjugate addition of Grignard reagents to cyclic and acyclic enones, with SimplePhos as chiral ligands. A variety of Grignard reagents can be added to a range of cyclic and acyclic enones, with moderate to good enantioselectivities (ee’s up to 86%).

  在本文中，我们报道了将格利雅试剂的铜催化不对称共轭加成到环状和非环状烯酮上，其中SimplePhos为手性配体。可以将各种格氏试剂添加到一系列环状和非环状烯酮中，具有中等到良好的对映选择性（ee高达86％）。
• PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20140206711A1

  公开（公告）日：2014-07-24

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α 2B , α 1B or α 2A . The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

  这份披露涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。提供了包括这些化合物的药物组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。这些化合物可以结合并拮抗受体α2B、α1B或α2A。这些化合物可以用于治疗，例如，（i）降低血压和/或（ii）促进肾血流和/或（iii）降低或抑制钠重吸收，或者调节血糖水平，增加胰岛素分泌，并治疗对增加胰岛素产生反应的疾病或状况。这些化合物还可以用于治疗预计会对降低血压产生反应的疾病或状况。特别描述了使用这些化合物治疗心血管、肾脏障碍或2型糖尿病的用途。
• PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Medivation Technologies, Inc.

  公开号：US20150258075A1

  公开（公告）日：2015-09-17

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

  本公开涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。所述化合物的制药组合物也提供，以及使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。该化合物可能结合并拮抗α2B、α1B或α2A受体。该化合物可能用于治疗，例如：（i）降低血压和/或（ii）促进肾血流和/或（iii）减少或抑制钠重吸收，或调节血糖水平，增加胰岛素分泌并治疗预计对胰岛素产生增加反应的疾病或情况。该化合物还可用于治疗预计对血压降低有反应的疾病或情况。特别描述了使用该化合物治疗心血管、肾脏疾病或2型糖尿病的用途。